Overview
Eliquis Regulatory Post Marketing Surveillance
Status:
Completed
Completed
Trial end date:
2017-09-29
2017-09-29
Target enrollment:
0
0
Participant gender:
All
All
Summary
The primary objective of this study is to examine the safety profile of Eliquis in Korean nonvalvular atrial fibrillation patients.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Bristol-Myers SquibbTreatments:
Apixaban
Criteria
For more information regarding BMS clinical trial participation, please visitwww.BMSStudyConnect.com
Inclusion Criteria:
- Patients ≥19 years of age
- Adult patients who are diagnosed with nonvalvular atrial fibrillation and are
initiating Eliquis anticoagulation therapy for risk reduction of stroke and systemic
embolism
- Patients with evidence of a personally signed and dated informed consent document
indicating that the patient (or a legally acceptable representative) has been informed
of all pertinent aspects of the study
Exclusion Criteria:
- Receiving Eliquis treatment for an indication that is not approved in Korea
- Contraindicated for the use of Eliquis as described in the Korean label